Allianz Asset Management
DAWN

Allianz Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Allianz Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,000
Closed -$198K – 2070
2025
Q1 		$198K Buy
+25,000
New +$269K ﹤0.01% 2138
2022
Q3 		– Sell
-51,325
Closed -$919K – 1939
2022
Q2 		$919K Buy
+51,325
New +$530K ﹤0.01% 1699

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management's DAWN Position: Q2 2025 in Review

Allianz Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2025, closing a stake of 25,000 shares — an estimated $198K sold.

Allianz Asset Management first reported a position in DAWN in Q2 2022 and held it in 2 quarters. The position peaked at $919K in Q2 2022. 174 funds tracked by Wall St. Rank hold DAWN as of Q2 2025.

  • Allianz Asset Management reported no remaining Day One Biopharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Allianz Asset Management sold 25,000 Day One Biopharmaceuticals shares in Q2 2025, an estimated $198K.
  • Allianz Asset Management first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Allianz Asset Management's Day One Biopharmaceuticals position peaked at $919K in Q2 2022.
  • 174 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2025.

Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.